Soleno Therapeutics, which develops drugs to treat rare genetic diseases, has seen its stock surge over 1,200% in the last year. In August, one of its drugs received Priority Review designation from the U.S. Food and Drug Administration (FDA). The medication is a pill designed to treat Prader-Willi syndrome, a…